Abstract
For over fifty years lithium has been a fundamental component of therapy for patients with bipolar disorders. Lithium has been considered recently for its potential to alleviate neuronal loss and other neurodegeneration processes. For instance, lithium reduces the severity of some behavioral complications of Alzheimers disease (AD). And there are growing indications that lithium may be of benefit to the underlying pathology of AD, as well as an array of other common CNS disorders, including stroke, Parkinsons disease, and Huntingtons disease. Despite these demonstrated and prospective therapeutic benefits, lithiums mechanism of action remains elusive, and opinions differ regarding the most relevant molecular targets. Lithium inhibits several enzymes; significant among these are inositol monophosphatase (IMPase), glycogen synthase kinase-3 (GSK-3), and the proteasome. Most recent publications discussing the medical application of lithium have converged on GSK-3, so this article reviews data and discussions regarding the roles and interactions of GSK-3 with other proteins and its proposed role in the pathogenesis of Alzheimers disease.
Keywords: Alzheimer disease, neuronal apoptosis, Tau Phosphorylation, Presenilin- 1, Amyloid beta
Current Alzheimer Research
Title: Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium
Volume: 4 Issue: 1
Author(s): Saeed Yadranji Aghdam and Steven W. Barger
Affiliation:
Keywords: Alzheimer disease, neuronal apoptosis, Tau Phosphorylation, Presenilin- 1, Amyloid beta
Abstract: For over fifty years lithium has been a fundamental component of therapy for patients with bipolar disorders. Lithium has been considered recently for its potential to alleviate neuronal loss and other neurodegeneration processes. For instance, lithium reduces the severity of some behavioral complications of Alzheimers disease (AD). And there are growing indications that lithium may be of benefit to the underlying pathology of AD, as well as an array of other common CNS disorders, including stroke, Parkinsons disease, and Huntingtons disease. Despite these demonstrated and prospective therapeutic benefits, lithiums mechanism of action remains elusive, and opinions differ regarding the most relevant molecular targets. Lithium inhibits several enzymes; significant among these are inositol monophosphatase (IMPase), glycogen synthase kinase-3 (GSK-3), and the proteasome. Most recent publications discussing the medical application of lithium have converged on GSK-3, so this article reviews data and discussions regarding the roles and interactions of GSK-3 with other proteins and its proposed role in the pathogenesis of Alzheimers disease.
Export Options
About this article
Cite this article as:
Yadranji Aghdam Saeed and Barger W. Steven, Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium, Current Alzheimer Research 2007; 4 (1) . https://dx.doi.org/10.2174/156720507779939832
DOI https://dx.doi.org/10.2174/156720507779939832 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glycogen Synthase Kinase-3 (GSK3) in Psychiatric Diseases and Therapeutic Interventions
Current Drug Targets Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology Alpha-1-Adrenergic Receptor Blockade Modifies Insulin-Regulated Aminopeptidase (IRAP) Activity in Rat Prostate and Modulates Oxytocin Functions
Drug Metabolism Letters Mitochondria as Targets for Neuronal Protection Against Excitotoxicity: A Role for Phenolic Compounds?
Central Nervous System Agents in Medicinal Chemistry Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets The Search for Immunosuppressive Therapies to Induce Tolerance in Organ Transplantation
Endocrine, Metabolic & Immune Disorders - Drug Targets Scientific Basis for the Use of Indian Ayurvedic Medicinal Plants in the Treatment of Neurodegenerative Disorders: 1. Ashwagandha
Central Nervous System Agents in Medicinal Chemistry Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry
Current Topics in Medicinal Chemistry Endothelial Dysfunction in Metabolic Diseases: Role of Oxidation and Possible Therapeutic Employment of N-acetylcysteine
Current Medicinal Chemistry Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets Nitric Oxide Releasing Nanomaterials for Cancer Treatment: Current Status and Perspectives
Current Topics in Medicinal Chemistry Recent Advances in the Development of Selective Ligands for the Cannabinoid CB2 Receptor
Current Topics in Medicinal Chemistry Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology?
Current Neuropharmacology Phenolic Acids Exert Anticholinesterase and Cognition-Improving Effects
Current Alzheimer Research Prolactin Protects Against the Methamphetamine-Induced Cerebral Vascular Toxicity
Current Neurovascular Research Eremurus spectabilis, Rich Source of Isoorientin: Isolation, Quantification and Anti-Cancer Activity on SH-SY5Y Neuroblastoma Cells
Current Pharmaceutical Analysis